BR112021023241A2 - Forma cristalina de brometo de sofpironium e método de preparação da mesma - Google Patents

Forma cristalina de brometo de sofpironium e método de preparação da mesma

Info

Publication number
BR112021023241A2
BR112021023241A2 BR112021023241A BR112021023241A BR112021023241A2 BR 112021023241 A2 BR112021023241 A2 BR 112021023241A2 BR 112021023241 A BR112021023241 A BR 112021023241A BR 112021023241 A BR112021023241 A BR 112021023241A BR 112021023241 A2 BR112021023241 A2 BR 112021023241A2
Authority
BR
Brazil
Prior art keywords
crystalline form
preparation
sofpironium bromide
sofpironium
bromide
Prior art date
Application number
BR112021023241A
Other languages
English (en)
Inventor
R Brinkman Herbert
Kazuyoshi MARUBAYASHI
Masahito Watanabe
Original Assignee
Brickell Biotech Inc
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brickell Biotech Inc, Kaken Pharma Co Ltd filed Critical Brickell Biotech Inc
Publication of BR112021023241A2 publication Critical patent/BR112021023241A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

forma cristalina de brometo de sofpironium e método de preparação da mesma. um cocristal contendo o 1'r-diastereômero e o 1's-diastereômero de brometo de sofpironium a uma razão de 1:3 (forma co), uma mistura de cristal (por exemplo, forma b) contendo a forma co e uma forma cristalina de 1'r-diastereômero (forma mn), e um método para preparar brometo de sofpironium, que é adequado para a fabricação da mistura de cristal são providos. a forma co e uma forma cristalina de brometo de sofpironium contendo a forma co (por exemplo, a forma b) têm estabilidade superior sem propriedade higroscópica e, portanto, podem ser de um modo preferido utilizadas como matéria-prima de medicamentos.
BR112021023241A 2019-05-23 2020-05-22 Forma cristalina de brometo de sofpironium e método de preparação da mesma BR112021023241A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
PCT/JP2020/020210 WO2020235665A1 (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Publications (1)

Publication Number Publication Date
BR112021023241A2 true BR112021023241A2 (pt) 2022-01-04

Family

ID=72146250

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023241A BR112021023241A2 (pt) 2019-05-23 2020-05-22 Forma cristalina de brometo de sofpironium e método de preparação da mesma

Country Status (16)

Country Link
US (3) US20220298108A1 (pt)
EP (1) EP3972955A4 (pt)
JP (2) JP6748329B1 (pt)
KR (1) KR20220011671A (pt)
CN (1) CN114008023B (pt)
AU (1) AU2020277881A1 (pt)
BR (1) BR112021023241A2 (pt)
CA (1) CA3139948A1 (pt)
CL (1) CL2021003047A1 (pt)
CO (1) CO2021017456A2 (pt)
IL (1) IL288285A (pt)
MX (1) MX2021014163A (pt)
SG (1) SG11202111678WA (pt)
TW (2) TWI838531B (pt)
WO (1) WO2020235665A1 (pt)
ZA (1) ZA202109514B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4002383A3 (en) 2020-11-13 2022-08-03 Tokyo Institute of Technology Information processing device, information processing method, recording medium recording information processing program, and information processing system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP5257073B2 (ja) * 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
US7399861B2 (en) * 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10906871B2 (en) * 2016-08-02 2021-02-02 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Also Published As

Publication number Publication date
WO2020235665A1 (en) 2020-11-26
CA3139948A1 (en) 2020-11-26
US20210395197A1 (en) 2021-12-23
US11566000B2 (en) 2023-01-31
TW202411205A (zh) 2024-03-16
JP2020189856A (ja) 2020-11-26
IL288285A (en) 2022-01-01
CL2021003047A1 (es) 2022-09-20
EP3972955A4 (en) 2023-07-05
ZA202109514B (en) 2023-12-20
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
SG11202111678WA (en) 2021-11-29
TWI838531B (zh) 2024-04-11
CN114008023A (zh) 2022-02-01
MX2021014163A (es) 2022-01-04
CO2021017456A2 (es) 2022-01-17
US20220298108A1 (en) 2022-09-22
JP6748329B1 (ja) 2020-08-26
US20210171460A1 (en) 2021-06-10
TW202110796A (zh) 2021-03-16
EP3972955A1 (en) 2022-03-30
KR20220011671A (ko) 2022-01-28
CN114008023B (zh) 2024-02-09
US11584715B2 (en) 2023-02-21

Similar Documents

Publication Publication Date Title
CR20210504A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
MX2021015936A (es) Metodos para preparar acido bempedoico y composiciones del mismo.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
UY28482A1 (es) Nuevos compuestos
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY28883A1 (es) Derivados de fenol y tiofenol 3-o 4-monosustituidos útiles como ligandos de h3
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
CY1113339T1 (el) Ιμιδαζοκινολινες με ανοσο-ρυθμιστικες ιδιοτητες
TW200616995A (en) Novel compounds
GEP20094664B (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
CR10056A (es) [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
AR080803A1 (es) Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias.
WO2012004714A3 (en) Benzene sulfonamides as inhibitors of voltage-gated sodium channels
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
HK1148517A1 (en) Tricyclic triazolic compounds
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
TW200639156A (en) New compounds
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
TW200605888A (en) Novel compounds
CR20210216A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
PH12018500377A1 (en) Novel annelated benzamides